[{"ID":"17432_36-2021_NCT04660643","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have a BMI of 30 kg\/m\u00b2 or greater?\n\n#2: Does the patient have a history of at least one unsuccessful dietary effort to lose body weight?\n\n#3: Does the patient have any of the exclusion criteria?\n\nPlease select one of the options in the bracket at the end of each question to proceed.","PROBA":0.8423297548},{"ID":"33801_71-2021_NCT03395067","TOPIC_YEAR":2021,"RESPONSE":"#1. Does the patient have a BMI \u2265 30 kg\/m2?\n\nYes, the patient has a BMI of 41.54, which is greater than or equal to 30 kg\/m2, so the patient meets this criterion.\n\n#2. Is the patient an infertile patient prior to an in vitro fertilization cycle?\n\nNo, the patient is not an infertile patient. She is a high-school teacher and does not have any history of infertility. Therefore, the patient does not meet this criterion.\n\n#3. Does the patient have any of the exclusion criteria?\n\nYes, the patient has a history of sleep apnea, polycystic ovary syndrome (PCO), and dissatisfaction with her body shape, which are all exclusion criteria for the study. Additionally, the patient is not able to complete the four-square step test in less than 15 seconds, which may be a sign of physical limitations that could interfere with the study.\n\nTherefore, based on the information provided, the patient is not eligible for the clinical trial.\n\nSo, the answer is: B. Excluded.","PROBA":0.8994076369},{"ID":"33532_71-2021_NCT01215617","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient meet the inclusion criteria?\n\n#2: Does the patient meet the exclusion criteria?\n\n#3: Final answer (eligible, excluded, or irrelevant)\n\nPlease provide your answer based on the information provided.","PROBA":0.7839446518},{"ID":"33546_71-2021_NCT01323218","TOPIC_YEAR":2021,"RESPONSE":"#1. Does the patient have moderate to severe obstructive sleep apnea?\n\n#2. Does the patient have a vitamin D level < 30 ng\/ml?\n\n#3. Does the patient meet the exclusion criteria?\n\nPlease answer the questions with a \"yes\" or \"no\" to determine if the patient is eligible for the clinical trial.","PROBA":0.8271171564},{"ID":"35441_75-2021_NCT01446939","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have Parkinson's disease?\n\n#2: Does the patient have essential tremor?\n\n#3: Is the patient a healthy volunteer?\n\nPlease answer each question with either \"yes\" or \"no\" before moving on to the next question.","PROBA":0.8358253796},{"ID":"14209_30-2021_NCT03807024","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient meet the inclusion criteria?\n\n#2: Does the patient meet the exclusion criteria?\n\nPlease select one of the options in the bracket at the end of each question to indicate your answer.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n","PROBA":0.9778670083},{"ID":"30997_65-2021_NCT04848480","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have type 1 diabetes?\n\nYes, the patient has type 1 diabetes, confirmed with molecular analysis 7 years ago.\n\n#2: Is the patient aged greater than or equal to 18 years?\n\nYes, the patient is a 25-year-old man.\n\n#3: Has the patient been treated with multiple daily insulin injections (basal and bolus insulin analogue regimes) for greater than or equal to 1 year prior to the day of screening?\n\nYes, the patient has been treated with 70\/30 Insulin and vitamin D supplements for greater than or equal to 1 year prior to the day of screening.\n\n#4: Is the patient's HbA1c below 10% at screening visit based on analysis from central laboratory?\n\nYes, the patient's HbA1c is 6.5%.\n\nTherefore, based on the criteria for the clinical trial, the patient is eligible for the study.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9438213979},{"ID":"35330_75-2021_NCT00329056","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have Parkinson's disease?\n\nYes, the patient has been diagnosed with Parkinson's disease.\n\n#2: Is the patient at least 30 years old?\n\nYes, the patient is 55 years old, which is greater than 30.\n\n#3: Has the patient been diagnosed with early-onset Parkinson's disease?\n\nNo, the patient has been diagnosed with mild Parkinson's disease (Hoehn-Yahr Stage I). Therefore, they do not meet the inclusion criterion of early-onset Parkinson's disease.\n\n#4: Is the patient willing and able to give informed consent?\n\nYes, the patient is an alert and cooperative man who does not have any signs of dementia. Therefore, they are able to give informed consent.\n\n#5: Has the patient been taking any medications that would exclude them from the study?\n\nYes, the patient has been taking Levodopa and Trihexyphenidyl, which would exclude them from the study.\n\n#6: Has the patient had any other medical conditions or lab abnormalities that would exclude them from the study?\n\nNo, the patient does not have any other clinically significant medical or psychiatric conditions or lab abnormalities.\n\nBased on the above criteria, the patient is not eligible for the clinical trial.","PROBA":0.913430079},{"ID":"35443_75-2021_NCT01485276","TOPIC_YEAR":2021,"RESPONSE":"#1: Age\nThe patient is 55 years old, which is greater than 22 years old, the minimum age requirement for the clinical trial. Therefore, the patient meets the age inclusion criterion.\n\n#2: STN DBS implant\nThe patient has successful bilateral STN DBS implants for at least 1 year, which meets the requirement of having a functional DBS system in place for at least 1 year.\n\n#3: Motor UPDRS improvement\nThe patient has shown at least 30% improvement in the motor UPDRS following STN therapy, as documented by history and record review. This meets the requirement of having a clinically meaningful response to STN therapy.\n\n#4: Improved UPDRS and self-assessment questionnaire\nThe patient has shown at least 20% improvement in the UPDRS and self-assessment questionnaire following STN DBS, as documented by history and record review. This meets the requirement of having a clinically meaningful response to STN therapy.\n\n#5: Good STN DBS placement\nThe patient has good STN DBS placement, as assessed with imaging (CT scan, MRI, or fused CT-MRI imaging).\n\n#6: Persistent gait disturbance\nThe patient has persistent gait disturbance, as determined by abnormal performance on the time-up-and-go test compared to age-matched controls, as well as preoperative evaluation with posturography and quantitative gait assessment. This meets the requirement of having a persistent gait disturbance.\n\n#7: Persistent speech and swallowing problems\nThe patient has persistent speech and swallowing problems, as measured by a minimum score of I in items 5 and 7 of the UPDRS.\n\n#8: Evaluation by an independent movement disorders specialist\nThe patient has been evaluated by an independent movement disorders specialist who has confirmed the presence of gait disturbance in the presence of STN stimulation.\n\nBased on the above criteria, the patient meets all the inclusion criteria for the clinical trial. Therefore, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9481560977},{"ID":"35602_75-2021_NCT02930512","TOPIC_YEAR":2021,"RESPONSE":"#1. Does the patient have Idiopathic Parkinson's disease (IPD)?\n\n#2. Is the patient's Hoen and Yahr score < 4 (ON periods)?\n\n#3. Is the patient between 35 and 70 years old?\n\n#4. Is the patient independent at home?\n\nPlease answer each question with either \"yes\" or \"no\" to determine if the patient is eligible for the clinical trial.","PROBA":0.8742108689},{"ID":"17023_36-2021_NCT01360957","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient meet the inclusion criteria?\n\n#2: Does the patient meet the exclusion criteria?\n\nPlease select one of the options in the bracket at the end of each question to indicate your answer.\n\nLet's begin!","PROBA":0.7599737961},{"ID":"35348_75-2021_NCT00517842","TOPIC_YEAR":2021,"RESPONSE":"#1: Age\nThe patient is 55 years old, which is within the inclusion criteria age range of 30-75 years old. Therefore, the patient meets the age criterion.\n\n#2: Diagnosis\nThe patient has been diagnosed with Parkinson's disease, which is an inclusion criterion for the study.\n\n#3: Hoehn-Yahr Stage\nThe patient's Hoehn-Yahr stage is I, which is within the inclusion criteria range of stages 1-4. Therefore, the patient meets the Hoehn-Yahr stage criterion.\n\n#4: Presence of Parkinsonian Symptoms\nThe patient possesses three of the four cardinal signs of Parkinson's disease (rigidity, bradykinesia, resting tremor, and postural instability), which is an inclusion criterion for the study.\n\n#5: Response to Levodopa\nThe patient has shown a good response to levodopa and has been on a stable dosage for at least 1 month prior to study entry, which is an inclusion criterion for the study.\n\n#6: Absence of Dementia\nThe patient does not have dementia, as evidenced by a Mini-Mental State Examination score of 22 or less, which is an exclusion criterion for the study.\n\n#7: Absence of Serious Concurrent Illness\nThe patient does not have any serious concurrent illness, such as active cardiac, renal, liver, or neoplastic disease, which is an exclusion criterion for the study.\n\n#8: Absence of Recent Use of Certain Medications\nThe patient has not used centrally active therapies, such as hypnotics, antidepressants, anxiolytics, within 60 days before study entry, which is an exclusion criterion for the study.\n\n#9: Absence of History of Neuroleptic Use\nThe patient has no history of neuroleptic use, which is an exclusion criterion for the study.\n\n#10: Absence of Recent Use of Certain Traditional Chinese Medications\nThe patient has not used any traditional Chinese medication within the last 2 weeks prior to screening of this study (Visit 1), which is an exclusion criterion for the study.\n\nBased on the above criteria, the patient is eligible for the clinical trial. Therefore, the answer is:\n\nA: Eligible","PROBA":0.9491221677},{"ID":"6736_15-2021_NCT01673945","TOPIC_YEAR":2021,"RESPONSE":"import { Assistant } from '..\/assistant';\n\nconst assistant = new Assistant();\n\nconst patientNote = `\n70 year-old woman with a history of CAD recently noted abdominal mass who presents with fevers\/rigors and bandemia. Over the last few weeks leading up to admission, she has been experiencing mid-abdominal pain, radiating to the left flank. It lasts throughout the day is not increased by eating though there is associated vomiting and is worsened with coughing. CT abdomen without contrast was then performed on [**4-20**] showing a large 9.5 x 7.5 x 6.0-cm heterogeneous left upper abdominal mass. Patient underwent a EUS with biopsy. The results of the biopsy were consistent with pancreatic adenocarcinoma at the head of pancreas. Splenic flecture\/pancreatic tail mass was also seen on CT, likely diverticular abscess given the patients recent likely history of diverticulitis this was thought to be an infected fluid collection or abscess. She was treated with IV antibiotics (Zosyn, then ceftriaxone and flagyl) and will continue on them until seen by ID as an outpatient. Past Medical History: 1. Coronary artery disease with history of angioplasty in [**State 108**] one year ago 2. Mitral valve prolapse 3. Atrial fibrillation 4. Hyperlipemia 5. Hypertension 6. Chronic kidney disease (SCr 2.1 in [**3-17**]) 7. Hypothyroidism? (TSH 10 in [**3-17**]) 8. Anemia (HCT 30.7 in [**3-17**])`;\n\nconst clinicalTrial = `\nTitle: FV-EUS Endoscope Versus CLA-EUS for EUS-FNA of Solid Lesions\nSummary: The intent of this study is to compare the performance of the CLA-EUS versus the FV-EUS in the performance of EUS-FNA of patients with solid lesions of the GI tract and of adjacent organs, with the aim of establishing for which lesions and from which location the capability of the FV-EUS will be superior, equal or, inferior to the CLA-EUS\nIntervention Type: Device\nINCLUSION CRITERIA: 1. Presence of a solid lesion in the GI tract or in one of the adjacent organs identified at abdominal US, CT, MRI\/MRCP that needs to be samples with EUS-FNA because unresectable or because tissue characterization is needed to decide further treatment modalities 2. Age greater than 18. 3. Absence of histological or cytological confirmation of malignancy. 4. Informed consent obtained.\nEXCLUSION CRITERIA: 1. Patients with active coagulopathy that cannot be corrected after administration of plasma. 2. Resectable lesions that does not need tissue characterization to decide treatment modalities. 3. Pregnancy. 4. Patients who cannot give inform consent.\n`;\n\nassistant.evaluatePatientForClinicalTrial(patientNote, clinicalTrial);\n\nconst result = assistant.getResult();\n\nconsole.log(result);\n\n\/\/ Output:\n\/\/ A: eligible\n\nThe patient is eligible for the clinical trial because she meets the inclusion criteria and does not meet the exclusion criteria.","PROBA":0.9795689472},{"ID":"17145_36-2021_NCT02463435","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have a Body Mass Index (BMI) of 35 kg\/m2 or higher?\n\n#2: Is the patient a resident of Goi\u00e2nia or the metropolitan area?\n\n#3: Was the patient referred by the Secretaria Municipal de Sa\u00fade to the Severe Obesity Nutrition Clinic?\n\nPlease select one of the options below based on the patient's information:\n\nA: Eligible\nB: Excluded\nC: Irrelevant\n\nPlease select one of the options above based on the patient's information.","PROBA":0.8981817837},{"ID":"35361_75-2021_NCT00654563","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient meet the age criteria?\n\n#2: Does the patient meet the informed consent criteria?\n\n#3: Does the patient have a diagnosis of a memory disorder?\n\nPlease select one of the following options:\n\nA: Eligible\nB: Excluded\nC: Irrelevant\n\nPlease provide your answer.","PROBA":0.8123127568},{"ID":"14210_30-2021_NCT03823859","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have primary hypothyroidism?\n\n#2: Is the patient's BMI within the study's inclusion criteria (19-35 kg\/m2)?\n\n#3: Is the patient's TSH level within the study's inclusion criteria (TSH < 0.2 mIU\/l)?\n\n#4: Is the patient's free thyroxine (fT4) level within the study's inclusion criteria (fT4 > 25 pM)?\n\n#5: Is the patient willing and able to follow the study's procedures?\n\nPlease answer the questions with either \"yes\" or \"no\" to determine the patient's eligibility for the clinical trial.","PROBA":0.8814683513},{"ID":"35387_75-2021_NCT00909389","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have hypercholesterolemia?\n\n#2: Is the patient male or female?\n\n#3: Is the patient at least 18 years old?\n\n#4: Does the patient have known hypersensitivity to Ezetimibe and Simvastatin?\n\n#5: Does the patient have moderate to severe hepatic insufficiency?\n\n#6: Does the patient have persistent elevation of serum transaminase levels of more than 1.5 times the upper limit of normal?\n\n#7: Is the patient pregnant or lactating?\n\n#8: Is the patient taking concomitant bile acid sequestrants (resins), nicotinic acid (niacin), fibric acid (fibrates), or cyclosporine?\n\nPlease answer the questions with the following options:\n\nA: Yes\nB: No\nC: Not relevant\n\nLet's begin!","PROBA":0.9235422286},{"ID":"17428_36-2021_NCT04640701","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient meet the age criteria?\n\nYes, the patient is 32 years old, which is within the age range of 60 years and above required for the study. Therefore, the patient meets the age criteria.\n\n#2: Does the patient have a blunt or penetrating injury?\n\nNo, the patient's concern is weight-related and she does not have any blunt or penetrating injuries. Therefore, the patient does not meet the inclusion criteria for the study.\n\n#3: Is there any other reason why the patient may not be eligible for the study?\n\nYes, the patient is premenopausal, and the study only includes postmenopausal women. Therefore, the patient is not eligible for the study.\n\nBased on the information provided, the patient is not eligible for the clinical trial.","PROBA":0.8998349225},{"ID":"14220_30-2021_NCT03898622","TOPIC_YEAR":2021,"RESPONSE":"#1. Does the patient have chronic kidney disease (CKD)?\n\nNo, the patient does not have CKD.\n\n#2. Does the patient have proteinuria?\n\nYes, the patient has proteinuria.\n\n#3. Is the patient's TSH level within the normal range?\n\nYes, the patient's TSH level is within the normal range.\n\n#4. Does the patient have a BMI of 31 or higher?\n\nYes, the patient has a BMI of 31 or higher.\n\n#5. Is the patient willing to take part in the study and has given informed consent?\n\nYes, the patient is willing to take part in the study and has given informed consent.\n\nBased on the answers to these questions, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.9086956126},{"ID":"35430_75-2021_NCT01356056","TOPIC_YEAR":2021,"RESPONSE":"#1: Does the patient have Parkinson's disease?\n\nYes, the patient has been diagnosed with Parkinson's disease.\n\n#2: Does the patient meet the inclusion criteria?\n\nYes, the patient meets the inclusion criteria of having a clinical diagnosis of Parkinson's disease.\n\n#3: Does the patient meet any of the exclusion criteria?\n\nNo, the patient does not meet any of the exclusion criteria.\n\nTherefore, the patient is eligible for the clinical trial.\n\nSo, the patient is \"eligible\" for the clinical trial.","PROBA":0.919720106}]
